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Abstract
Background: Chronic kidney disease (CKD) has been identified as a significant direct marker for cognitive decline,
but controversy exists regarding the magnitude of the association of kidney function with cognitive decline across
the different CKD stages. Therefore, the aim of this study was to investigate the association of kidney function with
cognitive decline in older patients at high risk of cardiovascular disease, using data from the PROspective Study of
Pravastatin in the Elderly at Risk (PROSPER).
Methods: Data of 5796 patients of PROSPER were used. Strata were made according to clinical stages of CKD
based on estimated glomerular filtration rate; < 30 ml/min/1.73m2 (stage 4), 30-45 ml/min/1.73m2 (stage 3b), 45-60
ml/min/1.73m2 (stage 3a) and ≥ 60 ml/min/1.73m2 (stage 1–2). Cognitive function and functional status was
assessed at six different time points and means were compared at baseline and over time, adjusted for multiple
prespecified variables. Stratified analyses for history of vascular disease were executed.
Results: Mean age was 75.3 years and 48.3% participants were male. Mean follow-up was 3.2 years. For all cognitive
function tests CKD stage 4 compared to the other stages had the worst outcome at baseline and a trend for faster
cognitive decline over time. When comparing stage 4 versus stage 1–2 over time the estimates (95% CI) were 2.23
(0.60–3.85; p = 0.009) for the Stroop-Colour-Word test, − 0.33 (− 0.66–0.001; p = 0.051) for the Letter-Digit-Coding
test, 0.08 (− 0.06–0.21; p = 0.275) for the Picture-Word-Learning test with immediate recall and − 0.07 (− 0.02–0.05;
p = 0.509) for delayed recall. This association was most present in patients with a history of vascular disease. No
differences were found in functional status.
Conclusion: In older people with vascular burden, only severe kidney disease (CKD stage 4), but not mild to
modest kidney disease (CKD stage 3a and b), seem to be associated with cognitive impairment at baseline and
cognitive decline over time. The association of severe kidney failure with cognitive impairment and decline over
time was more outspoken in patients with a history of vascular disease, possibly due to a higher probability of
polyvascular damage, in both kidney and brain, in patients with proven cardiovascular disease.
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Background
Both chronic kidney disease (CKD) and cognitive im-
pairment are increasingly prevalent with advancing age
and partly share a common cause as the kidney and the
brain share similar hemodynamic characteristics [1–3].
Both organs are low resistance end organs exposed to
high-volume blood flow and therefore predisposed for
vascular damage [4]. Next to aging, classical vascular risk
factors like hypertension, diabetes and a history of car-
diovascular diseases are associated with microvascular
damage and small vessel disease in both the kidney and
the brain [5–10].
Furthermore, CKD has been identified as a significant
marker for cognitive impairment [11, 12]. Although the
underlying pathophysiological mechanisms of cognitive dys-
function in CKD remain largely unknown, several candidate
mechanisms have been suggested apart from cardiovascular
risk factors, which are the same for kidney and brain. In
addition, nephrogenic risk factors as uremic toxins, oxidative
stress, anaemia, albuminuria and inflammation can lead to
cognitive impairment [10, 13]. Also in end-stage kidney dis-
ease determinants related to dialysis, such as intradialytic
hypotension or cerebral oedema can lead to cerebral hypo-
perfusion or neuronal damage [10, 12].
The prevalence and magnitude of the association of cog-
nitive impairment across different CKD stages is still sub-
ject of debate. Whereas the relationship has been firmly
established in patients with end-stage kidney disease, the
association of mild to modest impaired kidney function
with cognitive function remains questionable [14].
We hypothesized that with decreasing kidney function,
cognitive function declines faster over time. Therefore,
the aim of this study was to investigate the association
of the different stages of CKD and cognitive decline and
functional status in a high-risk population of older pa-
tients and furthermore, to investigate this association in
patients with a history of vascular disease, or patients
with only vascular risk factors, using data from the PRO-
spective Study of Pravastatin in the Elderly at Risk
(PROSPER).
Methods
The study population comes from PROSPER, a double-
blind, randomized, placebo-controlled trial, designed to
investigate the relationship between statin treatment and
the risk of cardiovascular and cerebrovascular events. In
summary, 5804 older participants (70–82 years) were en-
rolled in Ireland, Scotland and The Netherlands. Patients
were included if they had a history of, or an increased
risk for vascular disease and a baseline cholesterol be-
tween 4.0–9.0 mmol/l. A history of vascular disease in-
cluded stroke, transient ischemic attack, myocardial
infarction, arterial surgery, or amputation for vascular
disease less than 6 months before study entry. Increased
risk for vascular disease included current smoking,
hypertension, known diabetes mellitus or fasting blood
glucose levels over 7 mmol/L. Mean follow-up was 3.2
years. Detailed description of this population, including
all in- and exclusion criteria, has been published previ-
ously [15]. The study was approved by the institutional
ethics review boards of centres of Cork University
(Ireland), Glasgow University (Scotland) and Leiden
University Medical Center (the Netherlands). Consent
has been obtained from each patient or subject after
full explanation of the purpose and nature of all proce-
dures used.
Kidney function
At baseline creatinine levels were measured. Individuals
with baseline creatinine levels over 200 μmol/l were ex-
cluded. GFR was estimated using the Modification of
Diet in Renal Disease equation: eGFR = 186 x Scr(− 1.154)
x age(− 0.203) × 0.742 [if female], where Scr denotes serum
creatinine level in mg/dl. It is assumed that all partici-
pants were of Northern European descent [16]. Statis-
tical analysis of baseline characteristics was based on a
comparison among subgroups of clinical stages of kidney
failure based on eGFR, namely < 30 (CKD stage 4), 30–
45 (CKD stage 3b), 45–60 (CKD stage 3a) and ≥ 60ml/
min/1.73m2 (CKD stage 1–2) [17].
Cognitive function and functional status
Detailed description of the cognitive function and func-
tional status measurements in PROSPER has been pub-
lished previously [18, 19]. Measurement of cognitive
function and functional status were prespecified end-
points. One of the exclusion criteria was a poor cogni-
tive function at baseline, measured by the Mini-Mental
State Examination (MMSE). We used the generally used
cut-off point of 24 (of 30) points.
Outcome variables were derived from three other
widely used neuropsychological performance tests in dif-
ferent cognitive domains and two functional status tests,
as decline in functional status is largely driven by cogni-
tive impairment. First, executive functioning was
assessed using the Stroop Colour Word Test (Stroop)
and the Letter-Digit Coding Test (LDT). Selective atten-
tion was assessed using Stroop, which consist of three
parts, namely colour names, coloured patches and colour
names printed in incongruously coloured ink. The time
in seconds required to read the names or to identify col-
ours is recorded [20]. We used an abbreviated version of
the test with 40 elements [21]. Processing speed of gen-
eral information was assessed using the LDT, which is a
modification of the procedurally identical Symbol-Digits
Modalities Test, which has an outcome variable of total
number of correct entries completed in 60 s [22, 23].
Second, memory was assessed using the Picture-Word
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Learning Test. This verbal learning test is derived from
the Groningen 15 Words Test. Outcomes are measured
in three different trials and divided in recall (PLTi) and
delayed recall (PLTd) after 20 min [24–26]. Functional
status was assessed using two questionnaires, namely the
Barthel Index and the Lawton Instrumental Activities of
Daily Living Scale (IADL) [27, 28]. Barthel measures per-
formance in basic activities of daily living and consists of
10 items. Barthel scores range from 0 to 20, with lower
scores indicating more dependence. IADL evaluates
more complex instrumental activities and includes 7
items. IADL scores range from 0 to 14, with again lower
scores indicating more dependence. Cognitive function
and functional status were tested at several time points,
namely at baseline and after 9, 18 and 30months, and at
the end of the study.
Statistical analysis
All categorical data are presented as numbers with per-
centages and were compared using the chi-square test.
All continuous data are presented as mean ± standard
deviation or median with interquartile range and were
compared using an one-way ANOVA or Kruskal-Wallis
test.
Means of cognitive function test scores and functional
status scores at baseline were compared between the dif-
ferent CKD stages using a one-way ANOVA test. Fur-
thermore, severe CKD stage 4 was compared to stage 1–
2 (no CKD) using an independent t-test. For follow-up
linear mixed models for repeated measurements were
used, including the interim measures taken between the
baseline and the final assessment. This last measurement
varies between all participants between 36 and 48
months. Therefore all statistical analyses are performed
with their individually varying time point, but we graph-
ically display the results for the mean of these time
points at 42 months. To preclude possible learning ef-
fects the pre-randomized measurement was discarded in
all analyses. From the first PROSPER article about cog-
nitive function, we know that all cognitive tests show a
significant decline over time, confirming their adequate
sensitivity to pick up deterioration of cognitive function
in old age [19]. In the mixed model analyses CKD stages,
time and CKD stage * time were included. Furthermore,
to correct for confounders multiple prespecified fixed ef-
fects were included, namely sex, age, educational status,
country, statin treatment, vascular confounders includ-
ing history of vascular disease, hypertension, diabetes
and current smoking, and other known confounders in-
cluding objective measures as blood pressure, BMI,
baseline lipids, haemoglobin, urea, NT-proBNP and
troponin, all assessed as previously reported [15]. A log-
transformation will be used for the variables with skewed
distribution. Analyses will be repeated stratified for
subjects with or without a history of vascular disease.
The data were analysed using IBM SPSS Statistics ver-
sion 23. P-values lower than 0.05 were considered statis-
tically significant.
Results
Of the 5804 randomised patients, baseline creatinine
levels were available for 5796 participants (99.9%). Par-
ticipants had a mean age of 75.3 years and 48.3% were
male. Mean eGFR was 60.0 ± 14.6 ml/min/1.73m2. In the
prespecified stages of CKD, based on eGFR, 19 subjects
(0.33%) had a baseline eGFR of < 30ml/min/1.73 m2
(CKD stage 4), 786 (13.6%) an eGFR between 30 and 45
ml/min/1.73 m2 (stage 3b), 2306 (39.8%) an eGFR be-
tween 45 and 60ml/min/1.73 m2 (stage 3a), and 2685
(46.3%) an eGFR ≥60ml/min/1.73m2 (stage 1–2).
Baseline characteristics are shown in Table 1, over
strata of CKD stage and overall. Lower eGFR was signifi-
cantly associated with older age, female sex, less years of
education, more history of hypertension, vascular disease
and medication use, and less history of diabetes and
current smoking. Furthermore, lower eGFR was associ-
ated with an unfavorable lipid profile, higher levels of
CRP, urea, NT-proBNP and troponin-T and lower levels
of hemoglobin.
A higher score for Stroop or a lower score for the
other five tests indicate a worse cognitive function or
functional status. Non-adjusted baseline cognition and
functional status scores are shown in Table 2, over
strata of CKD stage and overall. The participants with
the most impaired kidney function (CKD stage 4) had
the worst cognitive function and functional status in
all domains at baseline. When comparing the CKD
stage 4 versus stage 1–2 mean scores (± SE) were
74.2 ± 6.7 vs 69.3 ± 0.6 for Stroop (p = 0.514), 21.9 ±
1.2 vs 21.9 ± 0.2 for LDT (p = 0.951), 8.6 ± 4.7 versus
9.2 ± 0.03 for PLTi (p = 0.146), 9.8 ± 0.8 vs 10.1 ± 0.04
for PLTd (p = 0.600), 19.7 ± 0.13 vs 19.8 ± 0.01 for
Barthel (p = 0.792) and 13.3 ± 0.31 vs 13.6 ± 0.02 for
IADL (p = 0.172).
Mean follow-up was 42 months with a range of 36–48
months. Figure 1 shows the effect of CKD stage on the
different cognitive function and functional status tests
over time. The mean cognition and functional status
scores are adjusted for all prespecified confounders. In
all cognitive function tests, a trend was seen for faster
cognitive decline over time in CKD stage 4 compared to
the other CKD groups. No differences were seen for
functional status. When comparing the most severe
CKD stage 4 (< 30 ml/min/1.73m2) versus stage 1–2 (>
60ml/min/1.73m2) over time the estimates (95% confi-
dence interval (CI)) are 2.26 (0.63–3.88; p = 0.007) for
Stroop, − 0.33 (− 0.66–0.00; p = 0.050) for LDT, 0.08 (−
0.06–0.21; p = 0.274) for PLTi, − 0.07 (− 0.27–0.13; p =
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0.503) for PLTd, − 0.01 (− 0.11–0.08; p = 0.766) for
Barthel and 0.03 (− 0.09–0.15; 0.622) for IADL, see also
Fig. 1. Participants with mild to modest CKD stage 3
compared to CKD stage 1–2 had no worse cognitive
function, which is also seen in Fig. 1, displaying practic-
ally parallel lines for CKD stages 3 to 1.
Stratification for history of vascular disease
In Fig. 2 the analysis was stratified according to the his-
tory of vascular disease. The trend of faster cognitive de-
cline over time in CKD stage 4 compared to the other
CKD groups was most prevalent in patients with a his-
tory of vascular disease compared to patients without a
Table 1 Baseline Characteristics Split by Baseline CKD stages and Overall
Total
n = 5796
CKD stages based on eGFR (ml/min/1.73m2) P-value*
Stage 4
n = 19
Stage 3b
n = 786
Stage 3a
n = 2306
Stage 1 and 2
n = 2685
Age (years) 75.3 ± 3.3 77.4 ± 3.1 76.8 ± 3.4 75.3 ± 3.3 74.9 ± 3.2 < 0.001
Male gender 2799 (48.3) 0 223 (28.4) 1029 (44.6) 1547 (57.6) < 0.001
Education (years) 15.1 ± 2.0 15.1 ± 1.8 14.8 ± 1.6 15.0 ± 1.8 15.4 ± 2.3 < 0.001
History of hypertension 3585 (61.9) 18 (94.7) 568 (72.3) 1471 (63.8) 1528 (56.9) < 0.001
History of diabetes 622 (10.7) 1 (5.3) 68 (8.7) 221 (9.6) 332 (12.4) 0.002
History of vascular disease 2561 (44.2) 7 (36.8) 400 (50.9) 1062 (46.1) 1092 (40.7) < 0.001
History of stroke or TIA 647 (11.2) 1 (5.3) 86 (10.9) 271 (11.8) 289 (10.8) 0.584
Current smoker 1558 (26.9) 4 (21.1) 131 (16.7) 558 (24.2) 865 (32.2) < 0.001
Number of medications 3.6 ± 2.3 5.2 ± 2.8 4.5 ± 2.3 3.7 ± 2.3 3.2 ± 2.2 < 0.001
SBP (mmHg) 154.7 ± 21.8 156.1 ± 27.3 154.8 ± 22.2 154.6 ± 21.5 154.6 ± 22.0 0.728
DBP (mmHg) 83.8 ± 11.4 82.5 ± 11.2 83.1 ± 10.7 83.6 ± 11.4 84.1 ± 11.6 < 0.001
BMI (kg/m2) 26.8 ± 4.2 26.6 ± 3.8 27.6 ± 4.4 26.8 ± 4.2 26.6 ± 4.1 < 0.001
LDL-C (mmol/l) 3.79 ± 0.80 4.06 ± 0.93 3.92 ± 0.81 3.85 ± 0.81 3.71 ± 0.78 < 0.001
HDL-C (mmol/l) 1.28 ± 0.35 1.29 ± 0.38 1.25 ± 0.34 1.28 ± 0.35 1.29 ± 0.35 < 0.001
Total cholesterol (mmol/l) 5.68 ± 0.91 6.02 ± 1.03 5.88 ± 0.94 5.74 ± 0.87 5.57 ± 0.87 < 0.001
Triglyceride (mmol/l) 1.54 ± 0.70 1.85 ± 0.74 1.76 ± 0.77 1.57 ± 0.69 1.46 ± 0.68 < 0.001
Glucose (mmol/l) 5.5 ± 1.4 5.13 ± 0.94 5.56 ± 1.40 5.50 ± 1.31 5.4 ± 1.6 < 0.001
CRP at 6 months (mg/l) 2.3 [1.1–4.5] 4.2 [2.1–10.1] 2.8 [1.4–5.7] 2.3 [1.1–4.6] 2.1 [1.0–4.1] < 0.001
Urea (mg/dL) 6.3 ± 1.8 10.5 ± 1.8 7.9 ± 2.3 6.4 ± 1.6 5.8 ± 1.5 < 0.001
Hb (mmol/L) 8.7 ± 0.8 8.4 ± 0.7 8.4 ± 0.8 8.7 ± 0.8 8.8 ± 0.8 < 0.001
NT-proBNP at 6 months (ng/l) 148.7 [79.5–289.3] 417.0 [283.9–789.0] 230.2 [122.1–489.1] 151.5 [81.4–293.9] 127.6 [70.0–238.8] < 0.001
Troponin at 6 months (μg/l) 0.010 ± 0.036 0.016 ± 0.010 0.013 ± 0.017 0.010 ± 0.042 0.010 ± 0.036 < 0.001
All values are presented as n (%), mean ± SD or median [IQR]. * p-values of categorical data were assessed using the chi-square test and p-values of the
continuous data were assessed using an one-way ANOVA test or a Kruskal-Wallis test. Abbreviations: BMI Body mass index, CKD Chronic kidney disease, CRP C-
reactive protein, DBP Diastolic blood pressure, eGFR Estimated glomerular filtration rate, Hb Haemoglobin, HDL High-density lipoprotein, LDL Low-density
lipoprotein, NT-proBNP N-terminal pro b-type natriuretic peptide, SBP Systolic blood pressure, SD Standard deviation, TIA Transient ischemic attack
Table 2 Cognitive Function at Baseline Over Strata of CKD stages and Overall
Total
n = 5796
CKD stages based on eGFR (ml/min/1.73m2) P-value*
Stage 4
n = 19
Stage 3b
n = 786
Stage 3a
n = 2306
Stage 1 and 2
n = 2685
Stroop-Colour-Word Test 66.5 ± 0.4 74.2 ± 6.7 66.4 ± 0.9 63.2 ± 0.5 69.3 ± 0.6 < 0.001
Letter-Digit Coding Test 23.1 ± 0.1 21.9 ± 1.2 23.3 ± 0.3 24.4 ± 0.2 21.9 ± 0.2 < 0.001
Picture-Word Learning Test – immediate 9.3 ± 0.03 8.6 ± 4.7 9.3 ± 0.07 9.4 ± 0.04 9.2 ± 0.03 0.001
Picture-Word Learning Test – delayed 10.1 ± 0.04 9.8 ± 0.8 10.0 ± 0.1 10.2 ± 0.05 10.1 ± 0.04 0.197
The Barthel index 19.8 ± 0.01 19.7 ± 0.13 19.7 ± 0.03 19.8 ± 0.01 19.8 ± 0.01 0.004
Instrumental Activities of Daily Living 13.6 ± 0.01 13.3 ± 0.31 13.5 ± 0.04 13.7 ± 0.02 13.6 ± 0.02 0.008
All values are presented as mean ± SE. * p-values of differences between groups were assessed using an one-way ANOVA test. Abbreviations: CKD Chronic kidney
disease, eGFR estimated glomerular filtration rate, SE Standard error
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Fig. 1 (See legend on next page.)
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history of vascular disease, see Fig. 2 and Table 3. No
differences were found for functional status. Estimates
(95% CI) of CKD stage 4 versus stage 1–2 in patients
with a history of vascular disease are 6.52 (3.94–9.10;
p < 0.0001) for Stroop, − 1.00 (−1.62 – − 0.37; p = 0.002)
for LDT, 0.16 (− 0.08–0.40; p = 0.180) for PLTi, − 0.02
(− 0.37–0.34; p = 0.930) for PLTd, 0.01 (− 0.16–0.18; p =
0.940) for Barthel and 0.06 (− 0.15–0.28; p = 0.562) for
IADL. Estimates (95% CI) of CKD stage 4 versus stage
1–2 in patients without a history of vascular disease are
− 0.11 (− 2.21–1.99; p = 0.919) for Stroop, − 0.08 (− 0.47–
0.32; p = 0.694) for LDT, 0.03 (− 0.13–0.20; p = 0.695) for
PLTi, − 0.09 (− 0.33–0.15; p = 0.485) for PLTd, − 0.02 (−
0.13–0.18; p = 0.642) for Barthel and 0.01 (− 0.12–0.15;
p = 0.868) for IADL, see also Table 3. Corresponding p-
values for interaction of vascular disease and cognitive
decline or functional decline over time were 0.016 for
Stroop, 0.115 for LDT, 0.529 for PLTi, 0.123 for PLTd,
0.737 for Barthel and 0.064 for IADL.
Discussion
In this large cohort of older people with an increased
risk for, or a history of, vascular disease, only severe kid-
ney disease (CKD stage 4), but not mild to modest kid-
ney disease (CKD stage 3a and b), was associated with
cognitive impairment at baseline and cognitive decline
over time. The association of severe kidney disease with
cognitive impairment and decline over time was more
outspoken in patients with a history of vascular disease.
No association was found between kidney function and
functional status.
Severe kidney failure as independent risk factor for
cognitive dysfunction, in combination with lack of effect
of the association of mild to modest kidney failure, has
been found in previous research [29, 30]. This might be
due to the fact that nephrogenic risk factors only start
playing a role in more advanced CKD [13]. Patients that
do have cognitive dysfunction in earlier stages of CKD
might have worse cognitive function mainly related to
vascular damage. Because it is known from previous
studies that a history of vascular disease or risk factors
as hypertension can lead to microvascular damage and
small vessel disease in the brain, CKD can ultimately
lead to cognitive dysfunction via this pathway [8, 9]. Fur-
thermore, impaired cardiac function, measured by NT-
proBNP or Troponin, is associated with cognitive dys-
function independently from other cardiovascular risk
factors [31–33]. As expected, also in this study, a poten-
tial predictor for worse cognitive function at baseline in
multivariate analysis was a higher vascular burden, as
shown before in this cohort [19, 34].
The contribution of kidney failure to cognitive dys-
function on top of a high vascular burden versus no vas-
cular burden remained hitherto mostly unknown. In
general, it is difficult to make a distinction between cog-
nitive decline in CKD patients with or without vascular
risk factors, because many CKD patients have a vascular
aetiology of their kidney failure, for instance due to
hypertension or diabetes mellitus. In this cohort 44.2%
of participants were included with a history of vascular
disease, 61.9% had hypertension and 10.7% had diabetes.
Therefore, we used stratification to distinguish patients
with proven vascular disease from patients with only
vascular risk factors. Cognitive function declined faster
over time in patients with CKD stage 4 (< 30ml/min/
1.73m2) especially together with a history of vascular dis-
ease. In a comparable subanalysis, Seidel et al. also showed
increasing prevalence of depression and cognitive dysfunc-
tion in the CVD group (defined as coronary heart disease
or myocardial infarction) compared to no CVD in the
higher CKD-stages compared to controls [35].
As previous research has been shown, decline in kidney
function associates with a higher risk of stroke, partly due
to a higher incidence in atrial fibrillation [36, 37]. Approxi-
mately 10% of patients develop new-onset dementia after
first stroke, and even more after recurrent stroke [38, 39].
According to the U.S. Renal Data System prevalence of
atrial fibrillation in patients with or without CKD is 24.0%
versus 9.5% and prevalence of CVA or TIA is 19.4% versus
7.7%. Prevalence of both diseases increases with increasing
stage of kidney failure [40]. Therefore, a history of stroke or
TIA, which is one of the inclusion criteria in this study,
could be a confounder considering the influence on cogni-
tive impairment. In the total group 11.2% had a history of
stroke or TIA, which did not differ significantly between
groups (p = 0.584); 1 (5.3%), 86 (10.9%), 271 (11.8%) and
289 (10.8%) in the CKD stage 4, stage 3b, stage 3a and stage
1–2 respectively. Therefore, the worse cognitive function in
CKD stage 4, appears unlikely to be explained by the preva-
lence of stroke or TIA.
(See figure on previous page.)
Fig. 1 Effect of CKD stage on cognitive function and functional status over time. * Means were assessed using linear mixed models adjusted for
prespecified variables including sex, age, educational status, country, statin treatment and multiple other known vascular confounders. P-values
represent the statistical significance of the difference in cognitive test score changes over time between CKD stage 4 (eGFR < 30 ml/min/1.73m2)
versus CKD stage 1–2 (eGFR> 60 ml/min/1.73m2). Abbreviations: Barthel, the Barthel index; eGFR, estimated glomerular filtration rate; IADL,
Instrumental Activities of Daily Living; LDT, Letter-Digit Coding Test; PLTd, Picture-Word Learning Test – delayed; PLTi, Picture-Word Learning Test
– immediate; Stroop, Stroop-Colour-Word Test
Zijlstra et al. BMC Nephrology           (2020) 21:81 Page 6 of 10
Fig. 2 (See legend on next page.)
Zijlstra et al. BMC Nephrology           (2020) 21:81 Page 7 of 10
Established previously in PROSPER, impaired kidney
function was independently associated with increased
risk of all-cause mortality, fatal vascular events and with
composite fatal and nonfatal coronary and heart failure
outcomes. This effect was most prevalent in eGFR < 40
ml/min/1.73m2. Notably, the PROSPER investigators did
not find an association between an impaired eGFR and a
higher risk of stroke [41]. However, not only impaired
kidney function increases the risk of mortality, but it is
also known, that next to the importance to prevent cog-
nitive decline for better quality of life of patients, a
worse cognitive function associates with higher morbid-
ity and mortality rates in older patients reaching end-
stage kidney disease [42–44].
The difference in cognitive decline for CKD stage 4
and CKD stage 1–2 might be partially explained by the
sex difference between the groups. However, a sex-
difference in cognitive decline is debated. A review
showed that sex did not determine the rate of cognitive
decline between ages of 60–80 years, an age that is com-
parable to our cohort that included patients between 70
and 82 years [45].. In our cohort univariate male sex cor-
related with worse cognitive function, however multi-
variate analysis showed still worse memory tests
compared to females, but better cognitive function in ex-
ecutive function (data not shown). These results are
comparable with a study by Proust-Lima et al., whereby
older women showed better outcomes in memory tests,
whereas men had a better visuospatial ability [46].
Therefore, the lack of males in the CKD stage 4 cannot
explain the worse outcome in that category.
Limitations
Our study has several limitations. First of all, our popu-
lation was selected for a specific clinical trial and do not
represent the general population.
Another limitation is that we were restricted to eGFR
in our measures of kidney function, other predictors as
albuminuria or cystatin C are not available. A recent
systematic review and meta-analysis of prospective,
population-based studies, showed that albuminuria
was most consistent as marker of CKD in the associ-
ation with cognitive decline with an odds ratio of 1.35
(95% CI 1.06–1.73). An eGFR < 60 ml/min/1.73m2
showed no significant association with cognitive dys-
function, consistent with our results, with an odds ra-
tio of 1.28 (95% CI 0.99–1.65) [47]. In our cohort the
same analyses with creatinine instead of eGFR yielded
similar results that were inversely proportional as ex-
pected (data not shown). Furthermore, no distinction
can be made between acute or chronic kidney failure.
Creatinine was only measured at baseline, so no
follow-up measurements are available, therefore it is
not known whether patients with a normal kidney
function at baseline deteriorated or patients with an
impaired kidney function improved over time. In
addition, it would be interesting to see whether pa-
tients with a faster cognitive decline also have a faster
decline in kidney function, considering that both the
brain and kidney share similar hemodynamic charac-
teristics, since both are low resistance end organs ex-
posed to high-volume blood flow and therefore
predisposed for vascular damage [4, 48].
Table 3 Effect of CKD stage 4 versus stage 1–2 on cognitive function over time
Total History of vascular disease No history of vascular
disease
interaction
Beta (95%CI) p-value Beta (95%CI) p-value Beta (95%CI) p-value p-value
Stroop-Colour-Word Test 2.26 (0.63–3.88) 0.007 6.52 (3.94–9.10) < 0.0001 − 0.11 (− 2.21–1.99) 0.919 0.016
Letter-Digit Coding Test − 0.33(− 0.66–0.00) 0.050 −1.00 (− 1.62 – − 0.37) 0.002 −0.08 (− 0.47–0.32) 0.694 0.115
Picture-Word Learning Test – immediate 0.08 (− 0.06–0.21) 0.274 0.16 (− 0.08–0.40) 0.180 0.03 (−0.13–0.20) 0.695 0.529
Picture-Word Learning Test – delayed −0.07 (− 0.27–0.13) 0.503 −0.02 (− 0.37–0.34) 0.930 −0.09 (− 0.33–0.15) 0.485 0.123
The Barthel index −0.01 (− 0.11–0.08) 0.766 0.01 (− 0.16–0.18) 0.940 −0.02 (− 0.13–0.08) 0.642 0.737
Instrumental Activities of Daily Living 0.03 (− 0.09–0.15) 0.622 0.06 (− 0.15–0.28) 0.561 0.01 (− 0.12–0.15) 0.868 0.064
* p-values of differences in cognitive test score changes over time were assessed between CKD stage 4 (eGFR < 30ml/min/1.73m2) versus CKD stage 1–2 (eGFR >
60ml/min/1.73m2) using linear mixed models adjusted for prespecified variables including sex, age, educational status, country, statin treatment and multiple
other known vascular confounders
(See figure on previous page.)
Fig. 2 Effect of CKD stage on cognitive function and functional status over time stratified for history of vascular disease. * Means were assessed
using linear mixed models adjusted for prespecified variables including sex, age, educational status, country, statin treatment and multiple other
known vascular confounders. P-values represent the statistical significance of the difference in cognitive test score changes over time between
CKD stage 4 (eGFR < 30 ml/min/1.73m2) versus CKD stage 1–2 (eGFR> 60ml/min/1.73m2). Abbreviations: Barthel, the Barthel index; eGFR,
estimated glomerular filtration rate; IADL, Instrumental Activities of Daily Living; LDT, Letter-Digit Coding Test; PLTd, Picture-Word Learning Test –
delayed; PLTi, Picture-Word Learning Test – immediate; Stroop, Stroop-Colour-Word Test
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Whereas one of the exclusion criteria was a high cre-
atinine at baseline and the groups of eGFR were divided
based on clinical stages, the group containing CKD stage
4 was relatively small (after stratification only seven par-
ticipants with and 12 participants without a history of
vascular disease). Therefore, although the results of CKD
stage 4 appear clinically relevant, especially in the cogni-
tive function analysis over time (Figs. 1 and 2), signifi-
cance remained partly absent and therefore results needs
to be interpreted with caution. Furthermore, although
the results of the cognitive function tests show the same
trend in both cognitive domains, the effect on executive
functioning seems statistically larger than the effect on
memory. Possible explanation could be that executive
functioning seems most often sooner affected than
memory, partly due to more sensitive executive function
tests, and memory would be more affected over a longer
follow-up period.
Conclusions
In this study, only severe kidney disease (CKD stage 4)
seem to be associated with cognitive impairment at base-
line and cognitive decline over time. A mild to modest
impaired kidney function appeared not to be independ-
ently associated with cognitive decline during a 3.2 year
follow-up period. For better understanding of the mech-
anisms involved in cognitive decline in CKD, especially
end-stage kidney disease, additional studies are neces-
sary, which may contribute to interventions for preven-
tion. Combined (metabolic) parameters of kidney
function, beside eGFR, should be taken into account, as
well as albuminuria. An observational study is currently
under way to gain insight in the potential different
mechanisms of cognitive decline in older patients with
end-stage kidney disease to identify modifiable risk fac-
tors [49]. Furthermore, it would be of great interest to
determine whether newer agents which seem to mean-
ingfully slow renal function decline such as SGLT2
inhibitors, also slow decline in cognitive function, al-
though we accept such agents may also lessens risks in
cardiovascular disease [50].
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